New Schizophrenia Genetic Mutation Discovered by Feinstein Institutes Researchers

New Schizophrenia Genetic Mutation Discovered by Feinstein Institutes Researchers

New Schizophrenia Genetic Mutation Discovered by Feinstein Institutes Researchers

MANHASSET, N.Y.–(BUSINESS WIRE)–Researchers at The Feinstein Institutes for Medical Research, in collaboration with Columbia University, have identified a gene mutation that could result in schizophrenia, a chronic brain disorder that affects nearly one percent of the world’s population. The findings, published today in Neuron, could lead to novel treatment strategies.

The research team, led by Todd Lencz, PhD, with Itsik Pe’er, PhD, Tom Maniatis, PhD, and Erin Flaherty, PhD, of Columbia University, carried out an innovative genetic study identifying a single letter change in the DNA code in a gene called PCDHA3 that is associated with schizophrenia. The affected gene makes a type of protein called a protocadherin, which generates a cell surface “barcode” required for neurons to recognize and communicate with, other neurons. They found that the PCDHA3 variant blocks this normal protocadherin function.

Past research has shown that genes play an important role in the disorder, but it has proven difficult to isolate individual genes that contribute substantial effects. These results indicate that further investigation into restoring communication between neurons could be a critical step in developing novel treatment options for schizophrenia.

The discovery was made possible by the special genetic characteristics of the samples studied by Dr. Lencz’s team; patients with schizophrenia and healthy volunteers drawn from the Ashkenazi Jewish population. The Ashkenazi Jewish population represents an important population for study based on its unique history. Just a few hundred individuals who migrated to Eastern Europe less than 1,000 years ago are the ancestors of nearly 10 million Ashkenazi Jews today. This lineage, combined with a tradition of marriage within the community, has resulted in a more uniform genetic background to identify disease-related variants.

“In addition to our primary findings regarding PCDHA3 and related genes, we were able – due to the unique characteristics of the Ashkenazi population – to replicate several prior findings in schizophrenia despite relatively small sample sizes,” said Dr. Lencz, professor in the Institute of Behavioral Science at the Feinstein Institutes. “In our study, we demonstrated this population represents a smart, cost-effective strategy for identifying disease-related genes. Our findings allow us to zero in on a novel aspect of brain development and function in our quest to develop new treatments for schizophrenia.”

Schizophrenia, characterized by delusions, hallucinations and disorganized thoughts and behavior is one of the leading causes for disability in the United States. Schizophrenia usually requires lifelong treatment, including medication and psychosocial therapy.

“Dr. Lencz’s research into the role of genetics in schizophrenia offers a major advance,” said Kevin J. Tracey, MD president and CEO of the Feinstein Institutes. “This work may open new avenues to developing therapeutics, which are sorely needed.”

This work was supported by a grant from the National Institute of Mental Health, as well as grants from the Brain & Behavior Foundation and the Binational Science Foundation. The study emerged from The Ashkenazi Genomics Consortium, a collaborative effort co-led by Dr. Lencz, involving more than a dozen investigators from leading institutions — including Columbia University, Mt. Sinai School of Medicine, Albert Einstein College of Medicine, and Weill Cornell Medical College — using similar strategies to understand the genetic basis of diseases including cancer, diabetes, and Parkinson’s disease.

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn.


Matthew Libassi